Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company focused on developing and commercializing central nervous system and other therapeutic drug candidates. Revenue, to the extent generated, is expected to come from commercial sales of approved products, with TONMYA (its fibromyalgia treatment) representing the first approved product entering commercial launch as of the fiscal year ended December 31, 2025. The company has no meaningful product revenue history disclosed in the filing excerpts and funds operations through public and private capital raises. Tonix holds exclusive license agreements with various institutions covering patents and technical information, with milestone obligations ranging from $25,000 to $5.0 million per agreement (as of December 31, 2025). Outstanding research and development contract commitments totaled approximately $52.3 million as of December 31, 2025. The company reported stock-based compensation of $6.0 million for the year ended December 31, 2025, split between general and administrative ($4.1 million) and research and development ($1.9 million). Tonix relies on third-party contract manufacturers and contract research organizations for drug production and clinical development.

Revenue model

Product sales from commercially launched drugs, with TONMYA for fibromyalgia as the first commercial product. No material product revenue is evidenced in the filing excerpts. The company has historically funded operations through equity and debt capital raises.

Products and services

TONMYA: FDA-approved treatment for fibromyalgia, entering commercial launch as of the fiscal year ended December 31, 2025. TNX-801: a medical countermeasure candidate for which the U.S. government is described as the primary market. Additional undisclosed pipeline candidates in research and development.

Customers and end markets

Fibromyalgia patients and prescribing physicians for TONMYA. U.S. government as the primary buyer for medical countermeasure candidate TNX-801. Third-party insurance companies and government agencies are identified as material reimbursement decision-makers.

Value-chain role

Drug developer and commercializer. Tonix outsources manufacturing to third-party contract manufacturers and clinical work to contract research organizations. It holds in-licensed intellectual property from academic and research institutions and seeks to develop, obtain regulatory approval for, and sell finished pharmaceutical products.

Geographic exposure

Primarily U.S.-focused based on disclosed regulatory and commercial activities. European regulatory pathways (EMA, EU Marketing Authorization) are referenced as potential future markets, but no approved products or revenue in foreign markets are evidenced in the filing excerpts.

Source: SEC 10-K, filed 2026-03-12

Industry: Pharmaceutical Preparations Peers: Elevation Oncology, Inc. Forum Markets, Inc Serina Therapeutics Inc GeoVax Labs Inc eFFECTOR Therapeutics, Inc. Oncotelic Therapeutics Inc Oncorus, Inc. Regulus Therapeutics Inc.